

Amedeo Lonardo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2339932/publications.pdf>

Version: 2024-02-01

165
papers

14,288
citations

18465

62
h-index

21521

114
g-index

169
all docs

169
docs citations

169
times ranked

14882
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. <i>Journal of Hepatology</i> , 2016, 65, 589-600.	1.8	965
2	Sex and gender: modifiers of health, disease, and medicine. <i>Lancet</i> , The, 2020, 396, 565-582.	6.3	955
3	Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome. <i>Digestive and Liver Disease</i> , 2015, 47, 181-190.	0.4	551
4	Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. <i>Hepatology</i> , 2019, 70, 1457-1469.	3.6	547
5	Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 936-944.	1.4	537
6	Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?. <i>Journal of Hepatology</i> , 2018, 68, 335-352.	1.8	495
7	Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 830-840.	1.4	467
8	Steatosis and hepatitis C virus: Mechanisms and significance for hepatic and extrahepatic disease. <i>Gastroenterology</i> , 2004, 126, 586-597.	0.6	433
9	NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. <i>Advances in Therapy</i> , 2017, 34, 1291-1326.	1.3	380
10	Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. <i>Digestive and Liver Disease</i> , 2015, 47, 997-1006.	0.4	368
11	From NAFLD in clinical practice to answers from guidelines. <i>Journal of Hepatology</i> , 2013, 59, 859-871.	1.8	304
12	Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2018, 14, 99-114.	4.3	284
13	Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2018, 79, 64-76.	1.5	261
14	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. <i>Digestive and Liver Disease</i> , 2017, 49, 471-483.	0.4	254
15	Nonalcoholic fatty liver disease and aging: Epidemiology to management. <i>World Journal of Gastroenterology</i> , 2014, 20, 14185.	1.4	227
16	Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 1724.	1.4	207
17	Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2010, 42, 272-282.	0.4	202
18	Non-alcoholic fatty liver disease and risk of cardiovascular disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1136-1150.	1.5	190

#	ARTICLE	IF	CITATIONS
19	Liver and diabetes. A vicious circle. <i>Hepatology Research</i> , 2013, 43, 51-64.	1.8	166
20	Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. <i>Atherosclerosis</i> , 2012, 221, 496-502.	0.4	164
21	Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. <i>Gut</i> , 2022, 71, 156-162.	6.1	162
22	Ultrasonographic fatty liver indicator, a novel score which rules out <sc>NASH</sc> and is correlated with metabolic parameters in <sc>NAFLD</sc>. <i>Liver International</i> , 2012, 32, 1242-1252.	1.9	155
23	Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. <i>Metabolites</i> , 2021, 11, 73.	1.3	145
24	Chronic hepatitis C virus infection and atherosclerosis: Clinical impact and mechanisms. <i>World Journal of Gastroenterology</i> , 2014, 20, 3410.	1.4	140
25	Nonalcoholic fatty liver disease: Evolving paradigms. <i>World Journal of Gastroenterology</i> , 2017, 23, 6571-6592.	1.4	138
26	Hepatic steatosis and insulin resistance: Does etiology make a difference?. <i>Journal of Hepatology</i> , 2006, 44, 190-196.	1.8	134
27	Hepatitis C and steatosis: a reappraisal. <i>Journal of Viral Hepatitis</i> , 2006, 13, 73-80.	1.0	131
28	Endocrine and liver interaction: the role of endocrine pathways in NASH. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009, 6, 236-247.	8.2	127
29	The independent predictors of non-alcoholic steatohepatitis and its individual histological features.. <i>Hepatology Research</i> , 2016, 46, 1074-1087.	1.8	124
30	Non-Organ-Specific Autoantibodies in Nonalcoholic Fatty Liver Disease: Prevalence and Correlates. <i>Digestive Diseases and Sciences</i> , 2003, 48, 2173-2181.	1.1	123
31	Statins in liver disease: A molehill, an iceberg, or neither?. <i>Hepatology</i> , 2008, 48, 662-669.	3.6	117
32	“Endocrine NAFLD”™ a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. <i>Journal of Hepatology</i> , 2006, 44, 1196-1207.	1.8	114
33	Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. <i>Atherosclerosis</i> , 2014, 232, 99-109.	0.4	113
34	Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases. <i>Metabolism: Clinical and Experimental</i> , 2017, 72, 57-65.	1.5	110
35	Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. <i>Digestive and Liver Disease</i> , 2002, 34, 204-211.	0.4	106
36	Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. <i>Hepatology</i> , 2016, 64, 1388-1389.	3.6	104

#	ARTICLE	IF	CITATIONS
37	Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 603-627.	1.4	102
38	Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD. <i>Current Pharmaceutical Design</i> , 2013, 19, 5177-5192.	0.9	100
39	Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1246-1267.	1.1	99
40	Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. <i>World Journal of Gastroenterology</i> , 2016, 22, 9674.	1.4	93
41	Fatty liver in heterozygous hypobetalipoproteinemia caused by a novel truncated form of apolipoprotein B. <i>Gastroenterology</i> , 1996, 111, 1125-1133.	0.6	91
42	Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Thyroid</i> , 2018, 28, 1270-1284.	2.4	87
43	Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research. <i>Journal of Clinical Medicine</i> , 2020, 9, 1278.	1.0	86
44	Right Colon Adenocarcinoma Presenting as <i>Bacteroides fragilis</i> Liver Abscesses. <i>Journal of Clinical Gastroenterology</i> , 1992, 14, 335-338.	1.1	85
45	Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. <i>Annals of Hepatology</i> , 2020, 19, 359-366.	0.6	81
46	Pathogenesis and significance of hepatitis C virus steatosis: An update on survival strategy of a successful pathogen. <i>World Journal of Gastroenterology</i> , 2014, 20, 7089.	1.4	81
47	Gallstone disease in non-alcoholic fatty liver: Prevalence and associated factors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 1176-1184.	1.4	80
48	Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2018, 87, 1-12.	1.5	80
49	NAFLD in Some Common Endocrine Diseases: Prevalence, Pathophysiology, and Principles of Diagnosis and Management. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2841.	1.8	79
50	Review article: hepatic steatosis and insulin resistance. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 64-70.	1.9	76
51	Genetic polymorphisms in non-alcoholic fatty liver disease: Interleukin-6 ^{rs174G/C} polymorphism is associated with non-alcoholic steatohepatitis. <i>Digestive and Liver Disease</i> , 2009, 41, 823-828.	0.4	76
52	History of Nonalcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5888.	1.8	74
53	Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?. <i>International Journal of Molecular Sciences</i> , 2016, 17, 217.	1.8	73
54	Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 629-650.	1.4	72

#	ARTICLE	IF	CITATIONS
55	Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD. <i>Current Pharmaceutical Design</i> , 2013, 19, 5177-5192.	0.9	72
56	A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?. <i>Acta Diabetologica</i> , 2019, 56, 385-396.	1.2	71
57	Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link?. <i>Journal of Endocrinological Investigation</i> , 2015, 38, 817-825.	1.8	70
58	Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?. <i>Endocrine</i> , 2016, 51, 211-221.	1.1	69
59	Hepatitis C and diabetes: the inevitable coincidence?. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 293-308.	2.0	66
60	Is nonalcoholic steatohepatitis associated with a high-through-normal thyroid stimulating hormone level and lower cholesterol levels?. <i>Internal and Emergency Medicine</i> , 2013, 8, 297-305.	1.0	66
61	Fatty Liver and Nonalcoholic Steatohepatitis. Where Do We Stand and Where Are We Going?. <i>Digestive Diseases</i> , 1999, 17, 80-89.	0.8	65
62	Should Nonalcoholic Fatty Liver Disease Be Renamed?. <i>Digestive Diseases</i> , 2005, 23, 72-82.	0.8	65
63	Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: An open question. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2007, 17, 684-698.	1.1	63
64	The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans. <i>Advances in Therapy</i> , 2016, 33, 291-319.	1.3	62
65	Metabolic alterations and chronic hepatitis C: treatment strategies. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2215-2234.	0.9	61
66	Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis. <i>Clinical Science</i> , 2008, 115, 1-12.	1.8	60
67	Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease. <i>Diagnostics</i> , 2021, 11, 98.	1.3	59
68	Potential for statins in the chemoprevention and management of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1654-1664.	1.4	58
69	Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes. <i>Atherosclerosis</i> , 2019, 284, 66-74.	0.4	58
70	A study of fatty liver disease and plasma lipoproteins in a kindred with familial hypobetalipoproteinemia due to a novel truncated form of apolipoprotein B (APO B-54.5). <i>Journal of Hepatology</i> , 2000, 33, 361-370.	1.8	57
71	A "systems medicine" approach to the study of non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2016, 48, 333-342.	0.4	56
72	Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient "death of a dogma from analysis of therapeutic studies?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2011, 5, 279-289.	1.4	55

#	ARTICLE	IF	CITATIONS
73	Phenotypic expression of familial hypobetalipoproteinemia in three kindreds with mutations of apolipoprotein B gene. <i>Journal of Lipid Research</i> , 2001, 42, 1552-1561.	2.0	55
74	Fatty liver, carotid disease and gallstones: A study of age-related associations. <i>World Journal of Gastroenterology</i> , 2006, 12, 5826.	1.4	53
75	Review article: the metabolic syndrome and non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 31-36.	1.9	51
76	Are there any sex differences in fatty liver? A study of glucose metabolism and body fat distribution. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 775-782.	1.4	50
77	Gender, fatty liver and GGT. <i>Hepatology</i> , 2006, 44, 278-279.	3.6	49
78	Are Routine Duodenal and Antral Biopsies Useful in the Management of "Functional" Dyspepsia?. <i>Journal of Clinical Gastroenterology</i> , 1993, 17, 101-108.	1.1	48
79	Cardiovascular and systemic risk in nonalcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD. <i>Current Pharmaceutical Design</i> , 2013, 19, 5177-92.	0.9	48
80	Clinical relevance of liver histopathology and different histological classifications of NASH in adults. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 351-367.	1.4	47
81	Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management. <i>Advances in Therapy</i> , 2021, 38, 2130-2158.	1.3	46
82	Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. <i>Metabolism: Clinical and Experimental</i> , 2020, 113, 154413.	1.5	45
83	Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity?. <i>Digestive and Liver Disease</i> , 2019, 51, 462-470.	0.4	44
84	Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review. <i>Advances in Therapy</i> , 2020, 37, 1910-1932.	1.3	40
85	Growth hormone plasma levels in nonalcoholic fatty liver disease. <i>American Journal of Gastroenterology</i> , 2002, 97, 1071-1072.	0.2	39
86	Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. <i>World Journal of Gastroenterology</i> , 2017, 23, 1458.	1.4	38
87	A critical appraisal of the use of ultrasound in hepatic steatosis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 667-681.	1.4	38
88	Association between <i>Helicobacter pylori</i> infection and risk of nonalcoholic fatty liver disease: An updated meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2019, 96, 56-65.	1.5	38
89	Familial heterozygous hypobetalipoproteinemia, extrahepatic primary malignancy, and hepatocellular carcinoma. <i>Digestive Diseases and Sciences</i> , 1998, 43, 2489-2492.	1.1	37
90	Metabolic concerns in aging HIV-infected persons. <i>Aids</i> , 2017, 31, S147-S156.	1.0	37

#	ARTICLE	IF	CITATIONS
91	Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infectionâ€”Liver: The â€œMusketeerâ€•in the Spotlight. International Journal of Molecular Sciences, 2016, 17, 355.	1.8	36
92	Treatment of Atherogenic Liver Based on the Pathogenesis of Nonalcoholic Fatty Liver Disease: A Novel Approach to Reduce Cardiovascular Risk?. Archives of Medical Research, 2011, 42, 337-353.	1.5	35
93	Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD). Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 353-358.	0.7	35
94	Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease. Future Medicinal Chemistry, 2019, 11, 2171-2192.	1.1	30
95	Hepatitis C Virus-Infected Patients Are â€˜Sparedâ€™™ from the Metabolic Syndrome but Not from Insulin Resistance. A Comparative Study of Nonalcoholic Fatty Liver Disease and Hepatitis C Virus-Related Steatosis. Canadian Journal of Gastroenterology & Hepatology, 2009, 23, 273-278.	1.8	27
96	Relationship of Serum Fetuin-A Levels with Coronary Atherosclerotic Burden and NAFLD in Patients Undergoing Elective Coronary Angiography. Metabolic Syndrome and Related Disorders, 2013, 11, 289-295.	0.5	26
97	â€œ Not all forms of NAFLD were created equal â€• Do metabolic syndrome-related NAFLD and PNPLA3-related NAFLD exert a variable impact on the risk of early carotid atherosclerosis?. Atherosclerosis, 2017, 257, 253-255.	0.4	26
98	HCV and diabetes. Digestive and Liver Disease, 2007, 39, 753-761.	0.4	25
99	Perspectives of nonalcoholic fatty liver disease research: a personal point of view. , 2020, 1, 85-107.		23
100	Dysmetabolic changes associated with HCV: a distinct syndrome?. Internal and Emergency Medicine, 2008, 3, 99-108.	1.0	22
101	Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment. Expert Review of Endocrinology and Metabolism, 2010, 5, 403-423.	1.2	22
102	Human Immunodeficiency Virus Is the Major Determinant of Steatosis and Hepatitis C Virus of Insulin Resistance in Virus-associated Fatty Liver Disease. Archives of Medical Research, 2011, 42, 690-697.	1.5	22
103	Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition?. Journal of Clinical Medicine, 2021, 10, 492.	1.0	22
104	Inflammatory hepatocellular adenomatosis, metabolic syndrome, polycystic ovary syndrome and non-alcoholic steatohepatitis: Chance tetrad or association by necessity?. Digestive and Liver Disease, 2014, 46, 288-289.	0.4	19
105	Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology, 2004, 39, 1748-1748.	3.6	18
106	Nonalcoholic fatty liver disease and COPD: is it time to cross the diaphragm?. European Respiratory Journal, 2017, 49, 1700546.	3.1	18
107	Metabolic-Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID Syndrome. Open Forum Infectious Diseases, 2022, 9, ofac003.	0.4	18
108	Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation. Nature Reviews Endocrinology, 2022, 18, 638-650.	4.3	18

#	ARTICLE	IF	CITATIONS
109	Nonalcoholic Fatty Liver Disease Is Associated With Higher 1-year All-Cause Rehospitalization Rates in Patients Admitted for Acute Heart Failure. <i>Medicine (United States)</i> , 2016, 95, e2760.	0.4	17
110	Pediatric gallstone disease in familial hypobetalipoproteinemia. <i>Journal of Hepatology</i> , 2005, 43, 188-191.	1.8	16
111	Hypothyroidism and nonalcoholic fatty liver disease – a chance association?. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2020, 41, .	0.3	15
112	Do Nonalcoholic Fatty Liver Disease and Fetuin-A Play Different Roles in Symptomatic Coronary Artery Disease and Peripheral Arterial Disease?. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 17.	1.0	15
113	Nonalcoholic fatty liver disease: does sex matter?. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 164-166.	0.7	15
114	How Much Vitamin D is Too Much? A Case Report and Review of the Literature. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2021, 21, 1653-1659.	0.6	15
115	The wide spectrum of steatohepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 1043-1050.	0.8	14
116	The Prevalence of Autoantibodies and Autoimmune Hepatitis in Patients with Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2005, 100, 1200-1201.	0.2	14
117	If steatosis is the atherosclerosis of the liver, are statins the “aspirin” for steatosis?. <i>Digestive and Liver Disease</i> , 2012, 44, 451-452.	0.4	13
118	Is Cholangiocarcinoma Another Complication of Insulin Resistance: A Report of Three Cases. <i>Metabolic Syndrome and Related Disorders</i> , 2007, 5, 194-202.	0.5	11
119	Statins and HCV: A complex issue. <i>Hepatology</i> , 2007, 45, 257-257.	3.6	11
120	The hepatitis C virus-associated dysmetabolic syndrome. <i>Hepatology</i> , 2008, 48, 1018-1019.	3.6	11
121	NAFLD and Cardiovascular Risk: Direct Evidence for the Tale of Two Ages. <i>American Journal of Gastroenterology</i> , 2009, 104, 1851-1852.	0.2	11
122	Do diabetes and obesity promote hepatic fibrosis in familial heterozygous hypobetalipoproteinemia?. <i>Internal and Emergency Medicine</i> , 2009, 4, 71-73.	1.0	10
123	Precision medicine in nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1175-1178.	1.4	10
124	Solitary Peutz-Jeghers Type Polyp of the Stomach. <i>Endoscopy</i> , 1990, 22, 153-153.	1.0	9
125	Isolated jejunal Crohn's disease in a young adult presenting as fever of unknown origin. <i>American Journal of Gastroenterology</i> , 1998, 93, 2285-2287.	0.2	9
126	Apolipoprotein synthesis in nonalcoholic steatohepatitis. <i>Hepatology</i> , 2002, 36, 514-515.	3.6	9

#	ARTICLE	IF	CITATIONS
127	Semi-Quantitative Ultrasonographic Evaluation of NAFLD. <i>Current Pharmaceutical Design</i> , 2020, 26, 3915-3927.	0.9	9
128	Nonalcoholic fatty liver disease activity score and Brunt's pathologic criteria for the diagnosis of nonalcoholic steatohepatitis: What do they mean and do they agree?. <i>Hepatology</i> , 2011, 53, 2142-2143.	3.6	8
129	Nonalcoholic steatohepatitis heralding olmesartan-induced sprue-like enteropathy. <i>Digestive and Liver Disease</i> , 2016, 48, 1399-1401.	0.4	8
130	Familial history in IBD. <i>Digestive Diseases and Sciences</i> , 1985, 30, 410-410.	1.1	7
131	Primary lymphoma of the spleen mimicking simple benign cysts: contrast-enhanced ultrasonography and other imaging findings. <i>Journal of Medical Ultrasonics</i> (2001), 2015, 42, 251-255.	0.6	7
132	NAFLD: Is There Anything New under the Sun?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1955.	1.8	7
133	Precision medicine approaches in metabolic disorders and target organ damage: where are we now, and where are we going?. , 0, , .		7
134	Intestinal Wegener's granulomatosis in a patient with severe alpha-1-antitrypsin deficiency resulting from a unique combination of two deficiency alleles (PiZ and PiMProcida). <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 1389-1392.	0.8	6
135	Chicken or egg turned into head or belly. <i>Journal of Hepatology</i> , 2006, 45, 454-456.	1.8	6
136	17beta-estradiol prevents cytotoxicity from hydrophobic bile acids in HepG2 and WRL-68 cell cultures. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 894-901.	1.4	6
137	Nonalcoholic Fatty Liver Disease in HIV-Infected Persons: Epidemiology and the Role of Nucleoside Reverse Transcriptase Inhibitors. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 53, 278.	0.9	6
138	Sofosbuvir-based therapy cures hepatitis C virus infection after prior treatment failures in a patient with concurrent lymphoma. <i>Journal of Clinical Virology</i> , 2015, 69, 74-77.	1.6	6
139	The "obese liver" and gastrointestinal cancer risk. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 44-44.	1.5	6
140	Non-alcoholic fatty liver disease (NAFLD) diagnosis and management" differentiating the essential from the ancillary and the present from the future. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 374-378.	0.7	6
141	Liver cirrhosis as A diabetogenic condition. <i>Digestive Diseases and Sciences</i> , 1986, 31, 111-111.	1.1	5
142	LETTER TO THE EDITOR. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1994, 9, 314-314.	1.4	5
143	The neck-liver axis. Madelung disease as further evidence for an impact of body fat distribution on hepatic histology. <i>Hepatology</i> , 2007, 47, 361-362.	3.6	5
144	Gamma glutamyl transferase: A novel cardiovascular outfit for an old liver test. <i>Indian Journal of Medical Research</i> , 2016, 143, 4.	0.4	5

#	ARTICLE	IF	CITATIONS
145	Of liver, whisky and plants: a requiem for colchicine in alcoholic cirrhosis?. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 355-358.	0.8	4
146	From a fatty liver to a sugary blood. <i>Digestive and Liver Disease</i> , 2018, 50, 378-380.	0.4	4
147	Cardiovascular Risk in NAFLD: An Intimate Relationship?. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1593-1595.	1.1	4
148	Back to the future: From the history of NAFLD to MAFLD to heterogeneity of disease. <i>Clinical and Translational Discovery</i> , 2021, 1, .	0.2	4
149	Hepatocellular carcinoma in a patient treated with efalizumab for psoriasis. <i>Hepatology Research</i> , 2012, 42, 945-945.	1.8	3
150	Telomere shortening: An innocent bystander at the crossroad of NASH with ageing and cardiometabolic risk?. <i>Liver International</i> , 2018, 38, 1730-1732.	1.9	3
151	Metabolomic signature: one step forward in the process of obtaining NAFLD patients's metabolic identity card. <i>American Journal of Clinical Nutrition</i> , 2022, 115, 603-605.	2.2	3
152	Lack of correlation between the laboratory findings and a series of steps in the clinical severity of chronic liver disease. <i>Research in Clinic and Laboratory</i> , 1984, 14, 641-8.	0.3	3
153	Article Commentary: Insulin Resistance, Type 2 Diabetes and Chronic Liver Disease. A Deadly Trio. <i>Clinical Medicine: Endocrinology and Diabetes</i> , 2009, 2, CMED.S3518.	0.3	2
154	NAFLD, Hepatotropic Viruses, and Cardiometabolic Risk. <i>Hepatology</i> , 2017, 65, 2122-2123.	3.6	2
155	LETTER TO THE EDITOR. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1994, 9, 663-664.	1.4	1
156	Is insulin resistance a pathogenic co-factor in hepatitis C virus-related disease and hepatocellular carcinoma?. <i>Digestive and Liver Disease</i> , 2002, 34, 151.	0.4	1
157	Fatty Liver and Carotid Intimal Thickening: A Tale of Two Ages?. <i>American Journal of Gastroenterology</i> , 2009, 104, 1061-1061.	0.2	1
158	Do ultrasonographic semiquantitative indices predict histological changes in <scp>NASH</scp> irrespective of steatosis extent?. <i>Liver International</i> , 2015, 35, 2340-2341.	1.9	1
159	Alcohol and Steatosis: The Japanese Paradox. <i>EBioMedicine</i> , 2016, 8, 23-24.	2.7	1
160	Noninvasive diagnosis of nonalcoholic fatty liver disease, is the more expensive the better?. <i>AME Medical Journal</i> , 0, 2, 171-171.	0.4	1
161	Methodological Tools for Exploring Novel Biopharmaceutical Approaches to the Metabolic Syndrome and Related Disorders. <i>Diabetes Therapy</i> , 2020, 11, 773-777.	1.2	1
162	Separating the apples from the oranges: from NAFLD heterogeneity to personalized medicine. <i>Exploration of Medicine</i> , 0, , .	1.5	1

#	ARTICLE	IF	CITATIONS
163	Use of procalcitonin for the differential diagnosis of fever in cancer patients: an observational study. Italian Journal of Medicine, 2013, , 166-171.	0.2	0
164	Clearing hepatitis C virus with direct antiviral agents reduces cardiovascular events in patients with prediabetes. Commentary to Sasso and colleagues. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2354-2357.	1.1	0
165	NAFLD in the 20â€™s. From Epidemiology to Management (PART - II). Current Pharmaceutical Design, 2020, 26, 3908-3908.	0.9	0